Andrx — Merger or Acquisition (March 2006)
39 slides from Andrx's merger presentation, Mar 30, 2006

Slide 1: A Brief Introduction to Watson
A BRIEF INTRODUCTION TO WATSON Allen Chao, Ph.D. Chairman & Chief Executive Officer March 30, 2006

Slide 2: Note Regarding Projections and Forward-Looking Statements
Note Regarding Projections and Forward-Looking Statements Any statement contained in this presentation that refers to Watson's estimated or anticipated future results, product development efforts, regulatory strategies, strategic initiatives, product launches, prospects for regulatory approval of it

Slide 3: Additional Information about the Transaction and Where to Find It
Additional Information about the Transaction and Where to Find It This slide presentation and conference call may be deemed to be solicitation material in respect of the proposed merger of Watson and Andrx. In connection with the proposed merger, Andrx will file a proxy statement with the U.S. Secur

Slide 4: Watson Corporate Headquarters - Corona, CA
Watson Corporate Headquarters - Corona, CA "Hwa's son" ^ "Watson"

Slide 5: Watson: A Brief History
Watson Pharmaceuticals was founded 1st ANDA approvals in '85 Acquired Schein Pharmaceuticals Acquired several brand products Added to NYSE (NYSE: WPI) Acquired Silodosin and TRELSTAR(r) 1984 1993 1997 1999 2000 2003 2004 2005 Listed on NASDAQ (NASDAQ: WATS) Acquired TheraTech FDA approval for OXYTRO

Slide 6: Clear, Consistent Strategy Since 1995
Clear, Consistent Strategy Since 1995 1995 2000 2003 Beyond Stage One Stage Two Stage Three Acquisitions establish Watson's market presence Build infrastructure to support growth of brand and generics Accelerate generics and brand revenue and margin growth Oclassen Royce Labs Rugby Group Co-Censys S

Slide 7: Watson Today
Watson Today * Reflects twelve months ended December 31, 2005 Watson is a leading $1.65B* specialty pharmaceutical company that develops and markets: One of the broadest lines of generic pharmaceutical products Specialty brand pharmaceutical products to treat diseases in the markets of: Urology Neph

Slide 8: FY 05 Revenue Grows to $1.65B
FY 99 FY 00 FY 01 FY 02 FY 03 FY 04 FY 05 Total Revenue 664.4 811.5 1160.7 1223.2 1457.8 1640.5 1646.2 FY 05 Revenue Grows to $1.65B CAGR = 16.3% 1999 - 2005 (in millions) $1,646MM

Slide 9: FY Revenue Breakdown
FY 05 Revenue Breakdown Generic Pharmaceuticals Brand Pharmaceuticals Other Revenue Revenue 1243 390 14 ($ Millions)

Slide 10: 4th Largest U.S. Generics Company, in TRxs
Source: IMS Health (Dec. 2005), * Includes Alpharma and Amide 380 228 209 94 83 89* 70 80 1 2 3 5 7 6 9 8 Market Position TRxs Dispensed (MM) Qualitest 197 4 46 10 4th Largest U.S. Generics Company, in TRxs 4th Largest U.S. Generics Company, in TRxs 4th Largest U.S. Generics Company, in TRxs

Slide 11: Watson's Dual Strategy: Committed to Both Brands and Generics
Watson's Dual Strategy: Committed to Both Brands and Generics Brands Longer product lifecycle Higher margins Focused portfolio strategy builds equity with physicians Generics The macro environment Large wave of blockbuster patent expirations Socio-economics point to increased utilization of generics

Slide 12: Current Operating Structure
Current Operating Structure Brand Division Oral Contraceptives Pain Management Anti-Inflammatory Antibiotics Hypertensives etc. Urology Nephrology Generic Division Finance - IT - Legal - HR - Sales Ops Shared Services

Slide 13: Current Manufacturing Technologies
Current Manufacturing Technologies Watson has manufacturing technologies in: Tablets Capsules Gum Transdermal patches Lozenges Gels, ointments, creams, etc. Gels, ointments, creams, etc. Gels, ointments, creams, etc. Gels, ointments, creams, etc. Gels, ointments, creams, etc. Gels, ointments, creams

Slide 14: Global Operations Today
? ? ? ? Global Operations Today ? Corona, CA Salt Lake City, UT Carmel, NY Copiague, NY Goa, India ? ? ? ? ? ? ? ? Coleraine, N. Ireland Mumbai, India Changzhou, China Morristown, NJ Brewster, NY Danbury, CT Gurnee, IL Mt. Prospect, IL

Slide 15: Global Product Development Centers
Global Product Development Centers Corona, CA Immediate/Sustained release Danbury, CT Immediate release Mumbai, India Immediate release Salt Lake City, UT Transdermals/gels

Slide 16: Global Manufacturing Centers
Global Manufacturing Centers Carmel, NY Solid dosage Copiague, NY Gum Corona, CA Solid dosage Changzhou, China API Coleraine, N. Ireland API Goa, India Solid dosage Mumbai, India API Salt Lake City, UT Transdermals/gels

Slide 17: Brand Division
@) WATSON Pharmaceuticals, Inc. BRAND DIVISION

Slide 18: Watson Brands: Today
Watson Brands: Today Specialty Products - Providing value and service to the urology community Oxytrol(r) / Kentera(tm) Trelstar(r) LA & Trelstar(r) Depot Androderm(r) Nephrology - Leader in IV iron replacement Ferrlecit(r) INFeD(r)

Slide 19: Watson Brands: New products in select therapeutic areas
Watson Brands: New products in select therapeutic areas Focus on specialty products Clinical differentiation Marketing skill Success Factors

Slide 20: Oxytrol International - A Broad Beginning
Oxytrol(r) International - A Broad Beginning Launches of Oxytrol(r) in Canada and Australia and launch of Kentera(tm) in Europe 2004 2005 2006* 2007* Canada Greece, Slovak Republic, Luxembourg Switzerland, Belgium Germany, UK, Ireland, Sweden, Norway, Finland, Denmark, Austria, Netherlands, Australi

Slide 21: Nephrology: Growing IV Iron Market
Q1 02 Q2 02 Q3 02 Q4 02 Q1 03 Q2 03 Q3 03 Q4 03 Q1 04 Q2 04 Q3 04 Q4 04 Q1 05 Q2 05 Q3 05 Q4 05 IV Iron Grams 258 257 247 251 267 274 269 255 281 281 282 300 309 319 308 322 * Source: IMS Health Data, month ended Nov 2005 Nephrology: Growing IV Iron Market Grams up 10%* YoY; Watson captures 53%* of

Slide 22: Watson Brands: R&D Pipeline
Watson Brands: R&D Pipeline Oxybutynin gel Silodosin Trelstar(r) line extension Licensing and other business development

Slide 23: Oxybutynin Gel Projected Timetable
Oxybutynin Gel Projected Timetable Efficacy Study Open Label NDA FDA Approval Q4 Q3 07 Q4 07 Q3 07 2006 2007 2008

Slide 24: Silodosin Projected Development Timetable
Silodosin Projected Development Timetable 2005 2006 2007 2008 2009 Efficacy Open Label Safety NDA FDA Approval Q2 Q4 07 Q2 08 Q4 06

Slide 25: Trelstar Life-Cycle
Trelstar(r) Life-Cycle Phase 4 underway to evaluate potential new indications Oncology Endometriosis Breast Cancer Option for longer acting formulation under development by Debiopharm

Slide 26: Generics Division
@) WATSON Pharmaceuticals, Inc. Generics DIVISION

Slide 27: Watson Generics: 2005
*Source: IMS Health Data thru Sept. '05 **Including 1 supplement and 2 amendments. Watson Generics: 2005 Over 10 billion units manufactured or distributed in 2005 Total prescriptions increased over 8% in last 12 months Launched 8 generic products 3 Approvals; 5 tentative approvals Filed 22** abbrevi

Slide 28: Watson Generics: Today
Watson Generics: Today Clearer focus in 2005 More efficient operations Significantly expanded R&D pipeline and productivity Strong customer service levels Good business partners

Slide 29: Generic Patent Challenges
Generic Patent Challenges Source: IMS Health Data, TTM, Dec. 2005; FTF = first to file opportunity; SE = shared exclusivity opportunity; TA = tentative Approval Sales ($M) EE/Levonorgestrel (Seasonale) - FTF $100 Testosterone Gel (Androgel) - FTF, approved $325 Rivastigmine (Exelon) - SE, TA $225 Pi

Slide 30: Watson Generics: Success Factors
Watson Generics: Critical mass Quality products Operating efficiencies Customer service Success Factors

Slide 31: Generic Company Pipelines Comparison
0 20 40 60 80 100 120 140 160 141 Teva 61 Ivax 52 Ranbaxy 49 Par 45 Dr. Reddy's 44 Mylan 35 Barr 30 Andrx 28 Auro- bindo 27 Eon 26 Sun Pharma Source: ABN AMRO Generic Company Pipelines (H1-2005) 40 Watson

Slide 32: Impact Of Newcomers Will First Be Felt In '06
Impact Of Newcomers Will First Be Felt In '06 Newcomers Company FY02 FY03 FY04 FY05 Pending Approval Established Sun Pharma 1 3 6 22 26 Glenmark - - - - - - 7 5 Cadila - - - - 12 13 20 Orchid - - - - - - 18 17 Lupin 2 3 - - 14 15 Aurobindo - - - - 2 22 28 Wockhardt - - 1 6 6 14 Subtotal 3 7 26 102 1

Slide 33: ...And The Chinese Are Gathering Steam
.... And The Chinese Are Gathering Steam Chinese DMF filings 5 10 15 20 25 30 35 40 45 1999 2% 4% 6% 8% 10% 12% 14% Filings from China (LHS) % of Total Filings 1H 2005 2004 2003 2002 2001 2000 Source: ABN AMRO

Slide 34: Watson Generics: Keys to Our Success
Watson Generics: Keys to Our Success Strong relationships with customers High service levels Large portfolio of products High product quality and consistency Competitive costs

Slide 35: Enhancing Competitiveness for Long Term Success
Enhancing Competitiveness for Long Term Success Active Pharmaceutical Ingredients (API) Partner with third parties Develop strategically selective APIs Improving efficiencies / cost management Manufacturing operations Facilities consolidation Building offshore capability

Slide 36: Generics Strategy
Generics Strategy Foundation for Near-Term & Long-Term Growth & Revenue Watson's Current Generics Operating efficiencies Asian Strategy Specialized Transdermal/Gels Product/Technologies Specialized Sustained Release Products/Technologies Solid dosage form Cost-Effective Operations

Slide 37: Generics Strategy: API to Finished Dosage Value Chain
Formulation Development Analytical Method Development Product Development Synthesis Production API Generics Strategy Watson China/Taiwan Develop & Manufacture APIs Watson India Develop & Mfg. Selected APIs Watson India Product Development Center Watson India Mfg. Finished Dosage Form Partners Watson

Slide 38: Watson: Well Positioned for Growth
Watson: Well Positioned for Growth Pipeline Strengthen pipeline of specialty products More than 40 ANDAs submitted Sales and Marketing Broad product offering for our customers API/ Cost of Goods Building offshore capabilities in India, Taiwan and China Brand business Steady performing business Expan

Slide 39: ©) WATSON
©) WATSON
Source: SEC EDGAR · DEFA14A filed Mar 30, 2006
